1. Market and Product Forecasts: Top 20 Oncology Therapy
Brands 2011-21 - Avastin fails to top any individual market in
2011
Report Details:
Published:September 2012
No. of Pages: 47
Price: Single User License – US$11400
The high level of commercial success experienced by the key companies in the cancer therapy
market makes the market extremely attractive to drug developers. Treatment of cancer has shifted
toward a more focused attack on the disease with targeted therapies. However, austerity
packages imposed could see slower commercial growth and larger generic erosion of key brands.
Features and Benefits
•Analysis of the top 20 oncology therapy brands in the seven major markets
•In depth analysis of the factors influencing the top 20 oncology brands in individual countries of
the seven major markets
•Sales forecasts for the top 20 cancer therapy brands from 2011 to 2021
•Brand dynamics and assessment of the top 5 cancer brands in the seven major markets
Highlights
The total sales of the top 20 cancer therapy brands in the seven major markets was $37.2bn in
2011, with targeted therapies representing 74% of those sales. However, the oncology market is
fragmenting as developers focus on niche subsets of patients with specific genetic mutations,
making it harder for drugs to reach blockbuster status.
Targeted therapies dominated the market, and will increase their share of the top 20 as patent
expiries continue to impact sales of other drug classes. Generic erosion of multiple key brands in
the cytotoxic class will be the key driver in decreasing its share of the top 20 branded sales from
17% in 2011 to 10% in 2021.
Avastin did not achieve the top position in any of the individual markets, the US, Japan, or 5EU,
due to a combination of US indication removal, cost-conservative EU markets, strong
antihormonal sales in Japan, and tough Swiss Franc exchange rates.
Your key questions answered

2. •Quantify the performance of each of the top 20 cancer therapy brands in the seven major markets
in 2011 and 2021.
•Acquire an account of top-selling cancer brand dynamics and the events that drive and limit their
market growth.
•The report is accompanied by a PowerPoint presentation and Excel deliverable showing full top
20 forecasts for the US, Japan and 5EU.
Get your copy of this report @
http://www.reportsnreports.com/reports/191886-market-and-product-forecasts-top-20-oncology-therapy-brands-
2011-21-avastin-fails-to-top-any-individual-market-in-2011.html
Major points covered in Table of Contents of this report include
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
MARKET DEFINITION
Market definition for cancer therapies
Antihormonal therapies by ATC class
Cytotoxic therapies by ATC class
Targeted therapies by ATC class
Forecast methodology and assumptions
Methodology flow
Patent expiries
Additional forecast methodology
MARKET OVERVIEW AND CONTEXT
Cancer therapy brands included in this report
Seven major markets top 20 oncology therapy brands
Targeted therapies will continue to control the seven major markets top 20
US top 20 oncology therapy brands
Cytotoxic brands lose out following patent expiries as targeted therapies fragment the
market
Japan top 20 oncology therapy brands
Patent expiries are likely to become more significant over the forecast period
Five major EU markets top 20 oncology therapy brands
Economic constraints limit sales growth of targeted therapies
PRODUCT FORECASTS
Brand dynamics
Avastin maintains overall leading position despite not topping any of the markets in 2011

3. Avastin (bevacizumab; Roche/Chugai)
Forecast assumptions
Avastin forecast 2011–21
Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)
Forecast assumptions
Rituxan forecast 2011–21
Herceptin (trastuzumab; Roche/Chugai)
Forecast assumptions
Herceptin forecast 2011–21
Gleevec (imatinib; Novartis)
Forecast assumptions
Gleevec forecast 2011–21
Revlimid (lenalidomide; Celgene)
Forecast assumptions
Revlimid forecast 2011–21
Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
Forecast assumptions
Erbitux forecast 2011–21
Lupron (leuprolide; Takeda/Abbott)
Forecast assumptions
Lupron forecast 2011–21
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
Forecast methodology
Volume and value forecast methodology
Price assumptions
TABLES
Table: Definition of the cancer market, 2012
Table: Patent expiry dates for antihormonal therapies in the top 20, 2011–21
Table: Patent expiry dates for cytotoxic therapies in the top 20, 2011–21
Table: Patent expiry dates for targeted therapies in the top 20, 2011–21
Table: Drugs included in the top 20 cancer therapy brands, 2011–21
Table: Sales of the top 20 cancer therapy brands in the seven major markets ($m), 2011
Table: Forecast sales of the top 20 cancer therapy brands in the seven major markets ($m),
2011–21
Table: Sales of the top 20 cancer therapy brands in the US, 2011
Table: Forecast sales of the top 20 cancer therapy brands in the US ($m), 2011–21
Table: Sales of the top 20 cancer therapy brands in Japan, 2011
Table: Forecast sales of the top 20 cancer therapy brands in Japan ($m), 2011–21

4. Table: Sales of the top 20 cancer therapy brands in the five major EU markets, 2011
Table: Forecast sales of the top 20 cancer therapy brands in the five major EU markets ($m),
2011–21
Table: Key branded cancer therapy sales in the seven major markets, 2011 and 2021
Table: Avastin sales, by market ($m), 2011–21
Table: Rituxan sales, by market ($m), 2011–21
Table: Herceptin sales, by market ($m), 2011–21
Table: Gleevec sales, by market ($m), 2011–21
Table: Revlimid sales, by market ($m), 2011–21
Table: Erbitux sales, by market ($m), 2011–21
Table: Lupron sales, by market ($m), 2011–21
FIGURES
Figure: Company-reported sales-based forecast methodology, 2012
Figure: Unevented and evented company-reported sales-based forecasts
Figure: Sales of the top 20 cancer therapy brands in the seven major markets, by drug class
($m), 2011 and 2021
Figure: Sales of the top 20 cancer therapy brands in the US, by drug class ($m), 2011 and
2021
Figure: Sales of the top 20 cancer therapy brands in Japan, by drug class ($m), 2011 and
2021
Figure: Sales of the top 20 cancer therapy brands in the five major EU markets by drug class
($m), 2011 and 2021
Figure: Key branded drug sales, 2011–21
Figure: Avastin sales, by market ($m), 2011–21
Figure: Rituxan sales, by market ($m), 2011–21
Figure: Herceptin sales, by market ($m), 2011–21
Figure: Gleevec sales, by market ($m), 2011–21
Figure: Revlimid sales, by market ($m), 2011–21
Figure: Erbitux sales, by market ($m), 2011–21
Figure: Lupron sales, by market ($m), 2011–21
Contact: sales@reportsandreports.com for more information.